Benjamin Edwards Inc. Acquires 12,359 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Benjamin Edwards Inc. lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 37.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,062 shares of the company's stock after purchasing an additional 12,359 shares during the period. Benjamin Edwards Inc. owned 0.05% of CRISPR Therapeutics worth $1,774,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after buying an additional 1,474,439 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after acquiring an additional 1,074,238 shares during the period. Capital International Investors increased its holdings in shares of CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after acquiring an additional 816,789 shares in the last quarter. Norges Bank acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $17,458,000. Finally, Contrarius Group Holdings Ltd acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $14,516,000. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Activity

In related news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock valued at $1,608,243 over the last quarter. Company insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

CRSP has been the subject of a number of recent research reports. Truist Financial boosted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. The Goldman Sachs Group lowered their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. HC Wainwright reiterated a "buy" rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. TD Cowen raised CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective for the company in a report on Wednesday, February 12th. Finally, Royal Bank of Canada dropped their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $72.84.

CRISPR Therapeutics Trading Up 3.3 %

Shares of NASDAQ CRSP opened at $34.27 on Thursday. The stock has a fifty day simple moving average of $38.43 and a two-hundred day simple moving average of $42.94. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -7.84 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The company's revenue for the quarter was up 71.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.43) earnings per share. Analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.